Web Date: May 19, 2014
AstraZeneca Rejects ‘Final’ Pfizer Offer
“We have rejected Pfizer’s final proposal because it is inadequate and would present significant risks for shareholders, while also having serious consequences for the company, our employees, and the life-sciences sector in the U.K., Sweden, and the U.S.,” AstraZeneca Chairman Leif Johansson said. Even if key concerns around a merger had been satisfactorily addressed, . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society